Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT4869
- Development stage
- Phase 2
- Lead developer
- Sumitomo Pharma
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal
01
Overview
WT4869 is an investigational cancer vaccine consisting of a peptide derived from the Wilms' tumor 1 (WT1) protein. Developed by Sumitomo Pharma (formerly Sumitomo Dainippon Pharma), it is primarily being evaluated for the treatment of myelodysplastic syndromes (MDS) and refractory anemia with excess blasts in transformation (RAEB-t). The vaccine is administered intradermally and functions by inducing a specific immune response, particularly the activation of WT1-specific cytotoxic T lymphocytes (CTLs), which target and destroy malignant cells overexpressing the WT1 antigen. WT1 is a transcription factor that is highly expressed in various hematological malignancies and solid tumors but has limited expression in normal adult tissues, making it a suitable target for immunotherapy.
- Other names
- WT1 peptide vaccineWT-1 peptide vaccineWT 1 peptide vaccineWT1 vaccineWT-1 vaccineWT 1 vaccine
02
Targets
WT1/HLA-A*24:02 (Wilms' tumor 1-derived peptide epitope presented by HLA-A*24:02)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on WT4869.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT4869.